Bayer is nearing the end of the road for glyphosate, executives say

Bayer is signaling it has had enough of litigation, leaving the future of a crop protection tool in limbo.

Executives tell the Wall Street Journal they are nearing the end of the road for glyphosate, the main ingredient in RoundUp. CEO Bill Anderson says they are barely breaking even, and litigation costs often put them in the red.

More than 65,000 cases are pending against Bayer right now, and the company has around $16 billion set aside for settlements.

Anderson stands by glyphosate, saying it has been proven safe to use, even by the FDA. Bayer produces roughly 40 percent of the supply used by U.S. farmers.

Related Stories
American Soybean Association President Caleb Ragland shares the soybean sector outlook following the announcement of farm aid to offset losses for U.S. row crop growers.
Sen. Deb Fischer, of Nebraska, mentioned that Congress pushing through year-round E15 sales will do more to help commodity growers than more farm aid, which is currently a reality.
Sen. Moran joins us to discuss the farm aid package and the financial reality faced by row crop farmers in his home state of Kansas.
Grain farms still have strong balance sheets, but another stretch of low profits will force hard cost cuts, especially on high-rent, highly leveraged operations.

LATEST STORIES BY THIS AUTHOR:

Plan for sharp, short-term volatility after unexpected outages; permanent closures rarely trigger major price spread disruptions.
American Farm Bureau Federation (AFBF) economist Danny Munch joined us on Thursday’s Market Day Report to break down the scope of the U.S. Christmas Tree industry and what growers are up against.
Canadian tariffs would raise costs for potash, ammonia, and UAN, increasing spring fertilizer risk.
Lewis Williamson with HTS Commodities breaks down the outlook on grain storage and domestic supply chain strength as producers weigh planting decisions with forthcoming federal aid.